Serum samples from 335 epileptic patients recervmg one or more anticonvulsant drugs, phenobarbitone, primidone and phenytoin, have been analysed for biochemical liver profile (BLP) and serum drug concentration.
Epileptic patients normally require long-term therapy with anti-convulsant drugs which frequently induce hepatic microsomal enzymes. With prolonged use of these drugs, the potential hazards of enzyme induction, which include drug interactions, I tolerance.i anti-convulsant osteomalacia,~folic acid deficiency, 4 interference with reference values" and hypertnglyceridemia," may be manifested in the patients. It is therefore essential to have a simple indicator of microsomal enzyme activity to show the degree of induction of hepatic microsomal enzyme systems at various stages of therapy.
The most common indirect method of assessing hepatic microsomal enzyme induction is the measurement of serum gamma glutamyltransferase (GGT; EC 2.3.2.2.) activity. Previous studies that have examined the association between GGT and hepatic microsomal enzyme activity have shown that the induction of serum GGT activity in patients varies widely."!" The different degrees of correlation of GGT activity with other indices of microsomal enzyme induction reported, question the use of GGT as a reliable index. The observation that no study has reported a HK)'Yo induction of GGT is of particular interest. Although various explanations such as patients' compliance, low * Present Address: Department of Chemistry. University of Science and Technology. PMB 5111«1. Port Harcourt, Nigeria. drug dosage and insufficient production of steroids have been presented to support the results, adequate reasons to account for the individual variations in the induction of GGT are still lacking.
This study investigates the factors affecting the relationship between serum GGT activity and anti-convulsant drug therapy. An attempt is also made to explain the results of previous studies based on the factors established by this study.
Methods
The serum from venous blood from epileptic patients on anti-convulsant drug therapy was separated by centrifugation at 2000 g for 5 min at 4°C and divided into two fractions: one fraction was labelled for BLP tests and the other for anti-convulsant drug analysis.
The control sample was taken from epileptic patients prior to treatment. Blood specimens were collected from this group of patients, 1 week, 3 months and 6 months after the start of anti-convulsant treatment.
The BLP tests performed were GGT, alanine transaminase (EC 2.6.1.2) alkaline phosphatase (EC 3.1.3.1) and bilirubin. All assays were performed at 37°C on a Technicon™ SMAC high speed computer-controlled analyser (Technicon Instruments Co. Ltd, Basingstoke, Hants, UK) using reagents prepared by Technicon.
The serum concentration of phenobarbitone, primidone and phenytoin was determined by gas liquid chromatography using a modification of the method of Helmsing, Van der Woude and Van Eupen.' , Gas liquid chromatography was performed isothermally on a Sigma I B series gas chromatograph (Perkin Elmer Ltd, Beaconsfield, UK) fitted with a flame ionisation detector.
The new epileptic patients, who gave informed consent for this study, were referred by consultant neurologists (Neurological Out-Patients Department, Leicester Royal Infirmary, Leicester, UK).
Statistical calculations were done on 10gItJ transformations of values. All results are expressed as mean 10gItJ values plus or minus 2 standard deviations (SO), with the figures in brackets showing corresponding ranges in the original scales.
A two way analysis of variance using the GUM Package was performed to test the effect of sex and age on the serum activity of GGT.
Results
Serum samples from 335 epileptic patients receiving one or more anti-convulsant drugs were analysed for BLP and drug concentrations. Nine of these showed two or more results outside the normal range for BLP and were therefore excluded.
Of the 326 patients with normal BLP, 168 were men with a mean log serum GGT activity fo 1·82±O·88 (8·71-5()]·19 lUlL) and 158 women with a mean log serum GGT activity of 1·71±O·78 (8·51-309·02 lUlL). The reference ranges of GGT activity established for hospital patients were I-50 lUlL for men and 1-35 lUlL for women.
Two hundred and sixteen (66°;',) patients had abnormally elevated serum GGT and were therefore regarded as having induced activity of GGT. Of this group 107 were men with a mean lot serum GGT activity of 2·IO±O·54 (36·30-436·50 lUlL) and 109were women with a mean log enzyme activity of 1·92±()·50 (26·3(~263·()3 lUlL).
THE EFFECT 01' ANTI-CONVULSANT DRUGS

ON SERUM GGT ACTIVITY
The effect of choice of anti-convulsant drugs administered on the induction of GGT activity in patients is shown in Table I . Of the 326 patients, 44% were taking phenobarbitone, 36% took phenytoin and the rest received drug combination of either phenobarbitonel phenytoin (18%) or phenobarbitone/primidone (2%). The highest proportion of patients with increased GGT activity was in the phenobarbitonelphenytoin group, whilst the group taking phenobarbitone alone had the lowest proportion. Chi-square (X 2 ) test showed that there was a significant (X 2 = 28·96, P«).()05) correlation between the choice of drug and increase in serum GGT activity in each group. Of the 216 patients with induced serum GGT activity, 42·12% were taking phenytoin and 33·08'Yo were taking phenobarbitone alone. Table 2 shows the mean log drug dosage per day and mean log serum GGT activity of patients.
EFFECT OF DAILY DOSE OF
ANTI-CONVULSANT
The 39 patients (information on drug dosage was provided for only 39 patients on phenobarbitone and 62 on phenytoin) on phenobarbitone had a mean log daily drug dosage of 1·94±O·52 (26·3(~288·40 mg) and mean log serum GGT activity of 1·61±O·68 (8·51-194·98 lUlL). The phenytoin group took a mean log anticonvulsant dose of 2·38±O·46 (83·18-6lJl·83 mg) per day and their mean log serum GGT activity was 1·95±O·68 (18·62-426·58 lUlL). Table 3 presents serum concentrations of phenobarbitone, phenytoin and GOT activity in patients who were taking the drugs singly. The men showed higher serum drug concentration with corresponding greater activity of OOT than the women. However. a linear regression analysis of the data showed that there was no significant correlation (P>IH/S) between serum drug concentration and GOT activity.
The distribution of" serum GOT activity by age of men and women epileptic patients is shown in Figs I and 2. The activity of OOT was lowest in the youngest age group of both men and women. In the 20-39 years age group, the distribution of OOT activity in both sexes showed a greater number of patients above the upper limit of normal than in the 0-19 years age group.
In the 40-59 years age group, although the proportion of patients with increased OOT activity was apparently the same, the men showed higher enzyme activity than the women. There was no difference between male and female epileptic patients over 60 years old either in the activity of GOT or in the proportion of patients in which this was elevated.
In order to investigate further the effects of age and sex on the serum activity of OOT. a two-way analysis of variance was performed using all data and subsets of data with serum GGT activity over 50 lUlL for men and 35 lUlL for women. Figure 3 shows that there is no significant difference between the fitted (expected) and true values of serum GGT activity for both men and women in the age groups. In order to ascertain whether the type of anti-convulsant drug administered was also responsible for the differences in GGT activity, data analysis relating the drug administered to sex was performed. Table 4 compares the induction of GOT activity in male and female epileptic patients on anti-convulsant therapy. The proportion of female patients with increased enzyme activity in each group except those taking phenobarbitone alone appeared greater than that of men. Table 5 shows the activity of serum GGT in patients who were followed before and after commencement of the anti-convulsant drugs therapy. No increase in OGT activity was observed after one week on treatment. After 3 months on anti-convulsants, only one patient showed remarkable increase in enzyme activity. Specimens for Patients I. 2 and 7 were not available for tests. By 6 months. there was an increase in GGT activity in three of the four patients whose specimens were provided. Although serum GGT activity was within the reference range in one of these patients. there had been almost a 100% increase in enzyme activity compared to the pre-treatment level. Patient 4. whose serum GGT activity was not increased after 6 months. was the only patient on phenobarbitone. whilst the other patients were on phenytoin.
SERUM GGT ACTIVITY IN NEW F.PII.EI'TlC
PATIENTS ON ANTI-CONVUI.SANT I)RUGS
Discussion
The results confirm previous studies 12 0-----0 men with serum GGT >50 (true); \J men with serum GGT >50 (fitted); e---e all women (true); -all women (fitted); e-----e women with serum GGT >35 (true); T women with serum GGT >35 (fitted). serum GGT activity in patients undergoing anti-convulsant drug therapy may depend on the age and sex of patients, choice of drug and duration of therapy. These factors may be interrelated.
THE EFFECT OF AGE
Reports on the effect of age on the induction of GGT activity have been contradictory. Schneblc!" did not observe any effect of age on the activity of GOT. Hcipeitz, Eickhoff and Poser!' reported that although there appeared to he a trend towards high GGT activities with advancing age, this was not statistically significant. However, Sano et (II Y clearly demonstrated an age effect. Whilst only 29% of their patients below the age of 20 years showed evidence of elevated GGT activity, 76'10 of the patients over 20 years had induced enzyme activity.
In the present study, the effect of age on the induction of GGT activity was clearly demonstrated. The proportion of patients with elevated GGT activity was significantly lower in the youngest age group.
The age effect may be related to other factors such as alcohol intake, other drugs and diseases that are likely to increase serum GGT activity. Since no attempt was made to alter the daily routine of the patients (especially the new epileptic group), these factors were not considered for the purpose of this study.
SEX DIFFERENCES
This study showed that the mean serum GGT activity in men is higher than in women. Aiges et al, also reported a similar result in a related study. Previous reports have suggested that hormonal differences might account for this observation since oestrogens act as OOT repressors or inhibitors in vivo and counteract the enzyme-inducing effect of the drugs. I? How the hormones inhibit the induction of GOT in women is not yet understood. IX Although numerous studies have demonstrated higher levels of GGT in men than women taking enzyme-inducing drugs, no study has compared these with pre-treatment levels. Thus, it cannot be stated that the degree of induction is greater in men. Although an attempt was made here for such a comparison, the number of patients available was too small for significant differences to he observed.
In the group of new epileptic patients, it was observed that the only male patient on phenobarbitone did not show any increase in serum GGT activity while all the women on phenytoin showed increase in GGT activity. This difference is suggested to have been caused by the choice of drugs.
CHOICE OF DRUGS
The serum GGT activity was higher in both men and women taking phenytoin than in those taking phenobarbitone. Similar observations have been made by Hisanaga et al.I'I and Sano et al. 15 to support the suggestion that phenytoin is a more effective inducer than phenobarbitone. However, an earlier report by Stevenson, O'Malley and Shepherd III showed that when the same dose of different anti-convulsant drugs were given to rats for the same duration, phenobarbitone showed a higher inducing potential than phenytoin. It therefore appears that the induction of serum GGT activity is not only related to the choice of anti-convulsant drug but also to the dose of the drug administered. This is evident from the fact that in the present study, patients taking phenytoin were given a higher dose of the drug and showed a greater increase in serum GGT activity than those on phenobarbitone.
DURATION OF THERAPY
This study showed that the likelihood of a patient having an increased serum GGT activity increased with duration of anti-convulsant treatment. In the group of eight patients investigated pre-and post-anti-convulsant treatment, it was observed that increase in serum enzyme activity mainly occurred 6 months after starting the drugs. This observation is also in line with that of Hisanaga et al." that the proportion of patients with elevated GGT activity is dependent on duration of the therapy.
Other studies have shown that different investigators report various degrees of GGT induction in various proportions of patients. Davidson, Mcintosh and Ford 7 in their study demonstrated a dose-related effect in that supervised in-patients showed a higher proportion of elevated GGT activities than the unsupervised out-patients whose compliance may have been poorer.
The 89% of patients with elevated GGT activity reported by Aiges et al, can be understood since only four of the 64 patients were taking phenobarbitone. Although it is not stated whether the four patients taking phenobarbitone are among those without elevated GGT activity.
The report by Bartels et al.x that 103 of the 120 patients showed increased serum enzyme activity demonstrated the influence of prolonged exposure to the drugs since 99 of the patients had been on therapy for over a year.
These examples demonstrate how various, often inter-related factors may influence the results of an investigation. These must be taken into consideration when studies are designed and the results interpreted.
